Access the full text.
Sign up today, get DeepDyve free for 14 days.
Andrew Tatem, Carlos Guerra, Peter Atkinson, Simon Hay (2004)
Athletics: Momentous sprint at the 2156 Olympics?Nature, 431
F. Cappuzzo, L. Bemis, M. Varella-Garcia (2006)
HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer.The New England journal of medicine, 354 24
A. Weickhardt, T. Price, G. Chong, V. Gebski, N. Pavlakis, T. Johns, A. Azad, E. Skrinos, Kate Fluck, A Dobrovic, R. Salemi, A. Scott, J. Mariadason, N. Tebbutt (2012)
Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 13
Stephens (2004)
Lung cancer: intragenic ERBB2 kinase mutations in tumoursNature, 431
S. Wang, A. Narasanna, Marianela Pérez-Torres, B. Xiang, Frederick Wu, Seungchan Yang, G. Carpenter, A. Gazdar, S. Muthuswamy, C. Arteaga (2006)
HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors.Cancer cell, 10 1
Weihua Zhang, R. Tsan, Wei‐Chien Huang, Qiuyu Wu, C. Chiu, I. Fidler, M. Hung (2008)
Survival of cancer cells is maintained by EGFR independent of its kinase activity.Cancer cell, 13 5
CASE REPORT Non–Small-Cell Lung Cancer with HER2 Exon 20 Mutation Regression with Dual HER2 Inhibition and Anti-VEGF Combination Treatment Gerald S. Falchook, MD,* Filip Janku, MD, PhD,* Anne S. Tsao, MD,† Christel C. Bastida, PhD,* David J. Stewart, MD,‡ and Razelle Kurzrock, MD§ dvances in cancer genome sequencing technologies have Sequenom MassARRAY analysis of the primary Aled to the identification of non–small-cell lung cancer tumor performed in a Clinical Laboratory Improvement (NSCLC) subtypes having distinct potentially actionable Amendments–certified laboratory showed a HER2 exon 20 molecular drivers, including mutations in the kinase domain mutation (insertion 774–775 AYVM) with no other mutations of human epidermal growth factor receptor-2 (HER2), which in an additional 52 tested oncogenes. have been reported in approximately 4% of NSCLC cases. In October 2011, after signing informed consent, the Preclinical and clinical studies demonstrated that HER2 muta- patient received therapy on a protocol approved by the M.D. tions in NSCLC are associated with a favorable response to Anderson Institutional Review Board (NCT00543504) with 2,3 HER2 targeted therapies. a combination of lapatinib, trastuzumab, and bevacizumab. Her baseline computed tomography (CT) of chest, abdo- men, and pelvis revealed metastatic lesions in the right lung, CASE STUDY and a magnetic resonance imaging (MRI) of brain showed a
Journal of Thoracic Oncology – Wolters Kluwer Health
Published: Feb 1, 2013
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.